Switching between thienopyridines in patients with acute myocardial infarction and quality of care
Francois Schiele, Etienne Puymirat, Laurent Bonello, Nicolas Meneveau, Jean-Philippe Collet, Pascal Motreff, Ramin Ravan, Florence Leclercq, Pierre-Vladimir Ennezat, Jean Ferrières, Tabassome Simon, Nicolas Danchin, Francois Schiele, Etienne Puymirat, Laurent Bonello, Nicolas Meneveau, Jean-Philippe Collet, Pascal Motreff, Ramin Ravan, Florence Leclercq, Pierre-Vladimir Ennezat, Jean Ferrières, Tabassome Simon, Nicolas Danchin
Abstract
Objective: In acute coronary syndromes, switching between thienopyridines is frequent. The aims of the study were to assess the association between switching practices and quality of care.
Methods: Registry study performed in 213 French public university, public non-academic and private hospitals. All consecutive patients admitted for acute myocardial infarction (MI; <48 hours) between 1/10/2010 and 30/11/2010 were eligible. Clinical and biological data were recorded up to 12 months follow-up.
Results: Among 4101 patients receiving thienopyridines, a switch was performed in 868 (21.2%): 678 (16.5%) from clopidogrel to prasugrel and 190 (4.6%) from prasugrel to clopidogrel. Predictors of switch were ST segment elevation MI presentation, admission to a cardiology unit, previous percutaneous coronary intervention, younger age, body weight >60 kg, no history of stroke, cardiac arrest, anaemia or renal dysfunction. In patients with a switch, eligibility for prasugrel was >82% and appropriate use of a switch was 86% from clopidogrel to prasugrel and 20% from prasugrel to clopidogrel. Quality indicators scored higher in the group with a switch and also in centres where the switch rate was higher.
Conclusions: As applied in the French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction (FAST-MI) registry, switching from one P2Y12 inhibitor to another led to a more appropriate prescription and was associated with higher scores on indicators of quality of care.
Figures
References
- Schiele F, Meneveau N. The role of the interventional cardiologist in selecting antiplatelet agents in acute coronary syndromes: a 10-question strategy. Eur Heart J Acute Cardiovasc Care 2012;1:170–6. 10.1177/2048872612450576
- Azmoon S, Angiolillo DJ. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheter Cardiovasc Interv 2013;81:232–42. 10.1002/ccd.24480
- Bagai A, Peterson ED, Honeycutt E et al. . In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 2015;4:499–508. 10.1177/2048872614564082
- Bagai A, Wang Y, Wang TY et al. . In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 2014;7:585–93. 10.1161/CIRCINTERVENTIONS.114.001555
- Hanssen M, Cottin Y, Khalife K et al. . French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010. Heart 2012;98:699–705.
- Flynn MR, Barrett C, Cosio FG et al. . The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J 2005;26:308–13. 10.1093/eurheartj/ehi079
- Wiviott SD, Braunwald E, McCabe CH et al. . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15. 10.1056/NEJMoa0706482
- Roe MT, Armstrong PW, Fox KA et al. . Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297–309. 10.1056/NEJMoa1205512
- Alexopoulos D, Goudevenos JA, Xanthopoulou I et al. . Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol 2013;168:5329–35. 10.1016/j.ijcard.2013.08.007
- Payne CD, Li YG, Brandt JT et al. . Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008;19:275–81. 10.1080/09537100801891640
- Wiviott SD, Trenk D, Frelinger AL et al. . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923–32. 10.1161/CIRCULATIONAHA.107.740324
- Angiolillo DJ, Saucedo JF, Deraad R et al. . Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010;56:1017–23. 10.1016/j.jacc.2010.02.072
- Montalescot G, Sideris G, Cohen R et al. . Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010;103:213–23. 10.1160/TH09-07-0482
- Wallentin L, Becker RC, Budaj A et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57. 10.1056/NEJMoa0904327
- Hamm CW, Bassand JP, Agewall S et al. . ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054. 10.1093/eurheartj/ehr236
- O'Gara PT, Kushner FG, Ascheim DD et al. . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–425. 10.1161/CIR.0b013e3182742cf6
- Steg PG, James SK, Atar D et al. . ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–619. 10.1093/eurheartj/ehs215
- Wright RS, Anderson JL, Adams CD et al. . 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:2022–60. 10.1161/CIR.0b013e31820f2f3e
- Spertus JA, Bonow RO, Chan P et al. . ACCF/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures. Circulation 2010;122:2091–106. 10.1161/CIR.0b013e3181f7d78c
- Steg PG, James SK, Atar D et al. . ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619. 10.1093/eurheartj/ehs215
- Windecker S, Kolh P, Alfonso F et al. . 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–619. 10.1093/eurheartj/ehu278
Source: PubMed